AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
Sponsored Reports
Loading...
| Previous Close (in USD) | 6.74 |
|---|---|
| Change | -0.125 1.855% |
| 52 W H/L (in USD) | 15.433/7.070 |
| EBITDA (in USD) | -27.719M |
| PE Ratio | -- |
| Volume | 552458 |
| Diluted Eps TTM | -1.05 |
| Total Assets (in USD) | 188.998M |
|---|---|
| Total Liabilities (in USD) | 209.687M |
| Revenue TTM (in USD) | 219.697M |
| Cash (in USD) | 62.838M |
| Market Cap (in USD) | 790.771 M |
| Revenue Per Share TTM | 3.821 |
| Gross Profit TTM (in USD) | 92.729M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Evolus Inc
Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
520 Newport Center Drive, Newport Beach, CA, United States, 92660
(949) 284-4555
Employees: 279
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. David Moatazedi | Pres, CEO & Director | 1978 |
| 2. | Dr. Rui Avelar C.CFP, Dip.SportMed, M.D. | Chief Medical Officer and Head of R&D | 1962 |
| 3. | Ms. Sandra Beaver | Chief Financial Officer | NA |
| 4. | Mr. David K. Erickson | VP of Investor Relations | NA |
| 5. | Mr. Jeffrey J. Plumer | Gen. Counsel | NA |
| 6. | Mr. Kurt Knab | VP of Sales | NA |
| 7. | Ms. Crystal Muilenburg | Chief Marketing Officer | 1980 |
| 8. | Ms. Jessica Novak | Sr. VP of HR | NA |
| 9. | Mr. David Moatazedi | President, CEO & Director | 1978 |
| 10. | Ms. Sandra Beaver | Chief Financial Officer | 1978 |
Peers
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
ZTS
Zoetis Inc |
+1.450 1.877% | 77.73 | 40.180 | 30.960 | 10.675 | 17.597 | 11.271 | 26.180 |
|
MKKGY
Merck KGaA ADR |
0.000 0.000% | 30.45 | 21.250 | 14.925 | 3.099 | 2.143 | 3.605 | 12.978 |
|
MKGAF
MERCK Kommanditgesellschaft auf Aktien |
0.000 0.000% | 157.12 | 21.730 | 14.948 | 3.159 | 2.147 | 3.562 | 12.822 |
|
GALDY
GALDERMA GROUP AG |
-0.330 0.763% | 43.55 | 74.210 | 41.667 | 8.636 | 5.553 | 9.151 | 42.220 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -74.317M | -46.768M | -162.936M | -105.061M | -46.802M |
| Minority Interest | - | - | - | - | - |
| Net Income | -74.412M | -46.81M | -163.013M | -90.034M | -46.867M |
| Selling General Administrative | 147.595M | 118.358M | 98.19M | 113.593M | 29.146M |
| Gross Profit | 92.729M | 56.139M | 38.241M | 26.911M | 0M |
| Reconciled Depreciation | 4.497M | 6.314M | 7.681M | 5.005M | 0.009M |
| Ebit | -57.575M | -63.615M | -68.698M | -94.787M | -45.939M |
| Ebitda | -59.498M | -64.282M | -59.029M | -92.976M | -45.93M |
| Depreciation And Amortization | -1.923M | -0.667M | 9.669M | 1.811M | 0.009M |
| Operating Income | -57.575M | -63.615M | -68.698M | -94.787M | -46.142M |
| Other Operating Expenses | 206.191M | 163.288M | 125.238M | 129.712M | 35.642M |
| Interest Expense | 9.097M | 1.396M | 10.503M | 7.953M | 0.863M |
| Tax Provision | 0.095M | 0.042M | 0.077M | -15.027M | 0.065M |
| Interest Income | 0.119M | 0.001M | 0.635M | 1.839M | 0.203M |
| Net Interest Income | -8.978M | -1.395M | -9.868M | -6.114M | -0.66M |
| Income Tax Expense | 0.095M | 0.042M | 0.077M | -15.027M | 0.065M |
| Total Revenue | 148.616M | 99.673M | 56.54M | 34.925M | 0M |
| Total Operating Expenses | 150.304M | 119.754M | 106.939M | 121.698M | 35.642M |
| Cost Of Revenue | 55.887M | 43.534M | 18.299M | 8.014M | 0M |
| Total Other Income Expense Net | -16.742M | 16.847M | -94.238M | -10.274M | -10.5M |
| Net Income From Continuing Ops | -74.412M | -46.81M | -163.013M | -90.034M | -46.867M |
| Net Income Applicable To Common Shares | -74.412M | -46.81M | -163.013M | -90.034M | -46.867M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 188.998M | 177.983M | 257.483M | 209.068M | 240.442M |
| Intangible Assets | 47.11M | 48.597M | 50.625M | 55.297M | 59.638M |
| Other Current Assets | 8.056M | 5.58M | 11.042M | 7.016M | 5.326M |
| Total Liab | 209.687M | 159.484M | 175.607M | 282.026M | 160.985M |
| Total Stockholder Equity | -20.689M | 18.499M | -422.882M | -376.072M | -213.059M |
| Other Current Liab | 31.61M | 2.449M | 42.373M | 72.888M | 17.443M |
| Common Stock | 0.001M | 0.001M | 0.001M | 0.001M | 0.001M |
| Capital Stock | 0.001M | 0.001M | 0.001M | 0.001M | 0.001M |
| Retained Earnings | -558.979M | -497.294M | -422.882M | -376.072M | -213.059M |
| Good Will | 21.208M | 21.208M | 21.208M | 21.208M | 21.208M |
| Other Assets | 0M | 2.813M | 32.543M | 3.654M | 2.429M |
| Cash | 62.838M | 53.922M | 146.256M | 102.562M | 109.892M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 48.291M | 46.509M | 57.663M | 180.248M | 24.439M |
| Current Deferred Revenue | 11.033M | 9.011M | 7.934M | 3.081M | - |
| Net Debt | 63.708M | 19.277M | -71.513M | 35.755M | -13.346M |
| Short Term Debt | 1.377M | 1.32M | 1.265M | 94.664M | 1.2M |
| Short Long Term Debt | - | - | - | 93.452M | - |
| Short Long Term Debt Total | 126.546M | 73.199M | 74.743M | 138.317M | 96.546M |
| Other Stockholder Equity | 538.716M | 516.129M | -0.001M | -0.001M | -0.007M |
| Property Plant Equipment | - | 2.616M | 1.371M | 4.711M | 4.97M |
| Total Current Assets | 112.421M | 100.802M | 178.799M | 127.612M | 152.197M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | 146.256M | 5M | 19.911M |
| Net Receivables | 30.529M | 22.448M | 14.657M | 9.68M | 10.661M |
| Long Term Debt | 120.359M | 71.879M | 71.222M | 40.506M | 91.453M |
| Inventory | 10.998M | 18.852M | 1.762M | 3.354M | 6.407M |
| Accounts Payable | 4.271M | 33.729M | 6.091M | 9.615M | 5.796M |
| Accumulated Other Comprehensive Income | -0.427M | -0.337M | - | - | 0.006M |
| Non Currrent Assets Other | 0.409M | 2.813M | 2.758M | 0.24M | 2.429M |
| Non Current Assets Total | 76.577M | 77.181M | 78.684M | 81.456M | 88.245M |
| Capital Lease Obligations | 6.187M | 2.544M | 3.521M | 4.359M | 5.093M |
| Long Term Debt Total | - | 71.879M | 71.222M | - | 91.453M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | -2.939M | 5M | 12.194M | -18.867M | -0.009M |
| Total Cashflows From Investing Activities | -2.939M | 4.03M | 12.194M | -23.434M | -0.009M |
| Total Cash From Financing Activities | -1.516M | 73.052M | 38.347M | 133.547M | 118.838M |
| Net Income | -74.412M | -46.81M | -163.013M | -90.034M | -46.867M |
| Change In Cash | -11.65M | 43.694M | -7.33M | 16.73M | 93.162M |
| Begin Period Cash Flow | 65.572M | 102.562M | 109.892M | 93.162M | 0M |
| End Period Cash Flow | 53.922M | 146.256M | 102.562M | 109.892M | 93.162M |
| Total Cash From Operating Activities | -8.774M | -33.388M | -57.871M | -93.383M | -25.667M |
| Depreciation | 4.497M | 6.314M | 7.681M | 5.005M | 0.009M |
| Other Cashflows From Investing Activities | -1.321M | -0.577M | -2.323M | -4.222M | - |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -10.688M | -2.979M | 4.542M | -4.482M | -4.482M |
| Sale Purchase Of Stock | - | 103.122M | - | 73.112M | 122.97M |
| Other Cashflows From Financing Activities | -2.055M | 66.039M | 38.869M | 61.276M | -0.172M |
| Capital Expenditures | 2.939M | 0.97M | 3.138M | 4.567M | 0.009M |
| Change In Working Capital | -34.251M | -11.543M | 35.602M | -20.807M | 2.792M |
| Other Non Cash Items | 84.577M | 9.06M | 51.25M | 17.99M | 11.363M |
| Free Cash Flow | -11.713M | -34.358M | -61.009M | -97.95M | -25.676M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 1512936 |
| 2. | iShares Russell 2000 ETF | 2 years ago | 994194 |
| 3. | Schroder US Smaller Companies Acc | 2 years ago | 764102 |
| 4. | Xtrackers S&P 500 Swap ETF 1C | 2 years ago | 731426 |
| 5. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 660511 |
| 6. | Nuveen Quant Small Cap Equity R6 | 2 years ago | 463370 |
| 7. | Fidelity Small Cap Index | 2 years ago | 424486 |
| 8. | Xtrackers MSCI World Swap ETF 1C | 2 years ago | 390052 |
| 9. | Oberweis Micro-Cap | 2 years ago | 371400 |
| 10. | Oberweis Micro-Cap Growth | 2 years ago | 371400 |
| 11. | iShares Russell 2000 Growth ETF | 2 years ago | 357582 |
| 12. | State St Russell Sm/Mid Cp® Indx NL Cl C | 2 years ago | 257796 |
| 13. | Fidelity Extended Market Index | 2 years ago | 255097 |
| 14. | Lord Abbett Micro Cap Growth I | 2 years ago | 193993 |
| 15. | Schroder U.S. Small Cap Core | 2 years ago | 182894 |
| 16. | Hartford Schroders US Small Cap Opps I | 2 years ago | 178931 |
| 17. | Vanguard Health Care ETF | 2 years ago | 165139 |
| 18. | Vanguard Russell 2000 ETF | 2 years ago | 157571 |
| 19. | State St Russell Sm Cap® Indx SL Cl I | 2 years ago | 146834 |
| 20. | NT R2000 Growth Index Fund - NL | 2 years ago | 123957 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Perceptive Advisors LLC | 2 years ago | 5753798 |
| 2. | TANG CAPITAL MANAGEMENT LLC | 2 years ago | 4147399 |
| 3. | BlackRock Inc | 2 years ago | 3339377 |
| 4. | Nantahala Capital Management, LLC | 2 years ago | 2910849 |
| 5. | Vanguard Group Inc | 2 years ago | 2905510 |
| 6. | Stonepine Capital Management Llc | 2 years ago | 2674356 |
| 7. | Morgan Stanley - Brokerage Accounts | 2 years ago | 2582711 |
| 8. | Great Point Partners LLC | 2 years ago | 2450000 |
| 9. | Caligan Partners LP | 2 years ago | 1888881 |
| 10. | Deutsche Bank AG | 2 years ago | 1414526 |
| 11. | State Street Corporation | 2 years ago | 1026374 |
| 12. | D. E. Shaw & Co LP | 2 years ago | 977578 |
| 13. | Millennium Management LLC | 2 years ago | 936373 |
| 14. | Geode Capital Management, LLC | 2 years ago | 934276 |
| 15. | Nuveen Asset Management, LLC | 2 years ago | 922904 |
| 16. | Rice Hall James & Associates, LLC | 2 years ago | 880744 |
| 17. | Soros Fund Management LLC | 2 years ago | 840100 |
| 18. | BOOTHBAY FUND MANAGEMENT, LLC | 2 years ago | 836925 |
| 19. | Schroder Investment Management Group | 2 years ago | 832798 |
| 20. | Lord, Abbett & Co LLC | 2 years ago | 830532 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...